Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

UnknownOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 27, 2018

Study Completion Date

September 30, 2018

Conditions
Rheumatoid Arthritis
Trial Locations (13)

E1G 2K5

Rhumatologie Moncton, Moncton

E2E 4J8

Eric N. Grant Professional Corp., Quispamsis

L1C 1P6

Bowmanville

L6T 3J1

Dr.'s Nalin and Vandana Ahluwalia Medicine Professional Corp., Brampton

K6V 5J9

Brockville Medical Centre, Brockville

L7L 0B7

The Arthritis Center, Burlington

N1H 5H8

St. Joseph's Health Care, Guelph

N6A 4V2

St-Joseph Health Center, London

L6E 0H7

N.R. Medical Clinic, Markham

M9C 5N2

Arthur Karasik Medicine Professional Corporation, Toronto

H2L 1S6

Institut de Rhumatologie de Montréal, Montreal

G1V 3M7

G.R.M.O. (Groupe de recherche en maladies oseuses) Inc., Québec

G1W 4R4

Centre de Rhumatologie St-Louis, Québec

Sponsors
All Listed Sponsors
lead

Pope Research Corporation

INDUSTRY

NCT01489384 - Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s) | Biotech Hunter | Biotech Hunter